Most Read Articles
2 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
Yesterday
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 5 days ago
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).

Pleuroparenchymal fibroelastosis tied to lower lung function, poorer prognosis in IPF patients

29 Sep 2020

Body mass index (BMI) and lung function are lower in patients with pleuroparenchymal fibroelastosis (PPFE) compared with those without, according to a study. The PPFE arm also has more frequent complications and poorer survival during follow-up.

The authors assessed the clinical significance of the radiologically defined PPFE in patients with idiopathic pulmonary fibrosis (IPF; mean age, 66.4 years; 76.4 percent male) by retrospectively analysing clinical data and chest CT images in 445 participants (biopsy-proven cases, n=165).

The radiological criteria of PPFE was defined as bilateral subpleural dense fibrosis with or without pleural thickening in the upper lobes, evidence of disease progression, and no clinical evidence of identifiable aetiologies.

Of the patients, 28 (6.3 percent) were identified to have PPFE. The median follow-up period was 43.0 months. Those with PPFE demonstrated lower BMI and lung function (ie, forced vital capacity and total lung capacity) at baseline, more frequent pneumothorax and pneumomediastinum, higher decline rates in lung function, and poorer prognosis during follow-up compared with patients without PPFE.

Notably, PPFE was independently associated with pneumothorax or pneumomediastinum (hazard ratio, 2.953, 95 percent confidence interval, 1.350–6.460; p=0.007), but not for mortality in patients with IPF.

“PPFE is characterized by fibrosis in the pleura and subpleural lung parenchyma in the upper lobes, while other types of interstitial lung disease, mainly usual interstitial pneumonia, can be observed in about half of the patients in their lower lobes,” the authors said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
Yesterday
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 5 days ago
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).